Table 1 Patient characteristics—3rd line treatment
Year started 3rd line | 2002–2006 | 2007–2012 | 2013+ | Total |
|---|---|---|---|---|
Number of patients | 73 | 198 | 73 | 344 |
Alive | 3 (4.1%) | 27 (13.6%) | 48 (65.8%) | 78 (22.7%) |
Dead | 70 (95.9%) | 171 (86.4%) | 25 (34.2%) | 266 (77.3%) |
Had regorafenib at any time | 2 (2.7%) | 48 (24.2%) | 61 (83.6%) | 111 (32.3%) |
Female | 31 (42.5%) | 77 (38.9%) | 39 (53.4%) | 147 (42.7%) |
Male | 42 (57.5%) | 121 (61.1%) | 34 (46.6%) | 197 (57.3%) |
Median age/range at start of treatment (3L) | 54.0 (18–90) | 58.2 (18–88) | 60.8 (19–84) | 57.8 (18–90) |
Age at diagnosis | ||||
 < 18 | 3 (4.1%) | 3 (1.5%) | 2 (2.7%) | 8 (2.3%) |
 ≥ 18–35 | 9 (12.3%) | 21 (10.6%) | 6 (8.2%) | 36 (10.5%) |
 ≥ 35 | 60 (82.2%) | 174 (87.9%) | 65 (89.0%) | 299 (86.9%) |
 Unknown | 1 (1.4%) | – | – |  |
Last reported treatment line | ||||
 3L | 35 (47.9%) | 57 (28.8%) | 39 (53.4%) | 131 (38.1%) |
 4L | 14 (19.2%) | 37 (18.7%) | 17 (23.3%) | 68 (19.8%) |
 5L | 11 (15.1%) | 32 (16.2%) | 9 (12.3%) | 52 (15.1%) |
 6L | 6 (8.2%) | 32 (16.2%) | 3 (4.1%) | 41 (11.9%) |
 7L | 5 (6.8%) | 19 (9.6%) | 4 (5.8%) | 28 (8.1%) |
 8L | 0 | 6 (3.0%) | 0 | 6 (11.9%) |
 9L | 2 (2.7%) | 8 (4.0%) | 1 (1.4%) | 11 (3.2%) |
 10L | 0 | 1 (0.5%) | 0 | 1 (0.3%) |
 11L | 0 | 3 (1.5%) | 0 | 3 (0.9%) |
 12L | 0 | 2 (1.0%) | 0 | 2 (0.6%) |
 13L | 0 | 1 (0.5%) | 0 | 1 (0.3%) |
Mutations/% (known mutations) | ||||
 KIT | 15 (78.9%) | 95 (75.4%) | 40 (75.5%) | 150 (75.8%) |
  Exon 11 | 10(52.5%) | 64 (50.8%) | 31 (58.5%) | 105 (53.0%) |
  Exon 9 | 5 (26.3%) | 25 (19.8%) | 7 (13.2%) | 37 (18.7%) |
  Exon 13 | – | 4 (3.2%) | 1 (1.9%) | 5 (2.5%) |
  Exon 17 | – | 1 (0.8%) | 1 (1.9%) | 2 (1.0%) |
 PDGFRA | 1 (5.3%) | 7 (5.6% | 4 (7.5%) | 12 (6.1%) |
  Exon 12 |  | 1 (0.8%) | – | 1 (0.5%) |
  Exon 18–D842V | 1 (5.3%) | 5 (4.0%) | 3 (5.6%) | 9 (4.5%) |
  Exon 18 non-D842V |  | 1 (0.8%) | 1 (1.9%) | 2 (1.0%) |
Wildtype for KIT/PDGFRA | 3 (15.8%) | 22 (17.5%) | 7 (13.2%) | 32 (16.2%) |
SDHA | – |  | 2 (3.8%) | 2 (1.0%) |
SDHB | – | 2 (1.6%) | – | 2 (1.0%) |
Total/% known mutations | 19 (26%) | 126 (63.6%) | 53 (72.6%) | 198 (57.6%) |
Unknown mutations | 54 (74.0%) | 72 (36.4%) | 20 (27.4%) | 146 (42.4%) |
Primary tumor location | ||||
 Small intestine | 32 (43.8%) | 85 (42.9%) | 34 (46.6) | 151 (43.9% |
 Stomach | 27 (37.0%) | 81 (40.9%) | 29 (39.7%) | 137 (39.8%) |
 Unknown | 7 (9.6%) | 10 (5.1%) | 2 (2.7%) | 19 (5.5%) |
 Peritoneum | 1 (1.4%) | 2 (1.0%) | 3 (4.1%) | 6 (1.7%) |
 Omentum | 1 (1.4%) | 3 (1.5%) | 1 (1.4%) | 5 (1.5%) |
 Mesentery | 1 (1.4%) | 4 (2.0%) | – | 5 (1.5%) |
 Rectum/anus | 1 (1.4%) | 3 (1.5%) | 1 (1.4%) | 5 (1.5%) |
 Colon | – | 5 (2.5%) | – | 5 (1.5%) |
 Other | 3 (4.1%) | 5 (2.5%) | 3 (4.1%) | 11 (3.2%) |